Clinical trial results:
A pilot study into health pre and post treatment with intravenous Aminophylline and Hydrocortisone in severe asthmatics

Summary

EudraCT number	2014-000182-45
Trial protocol	GB
Global end of trial date	26 February 2015

Results information

Result version number	v1 (current)
This version publication date	03 October 2020
First version publication date	03 October 2020
Summary attachment (see zip file)	05.03.2015_End of Trial Declaration (05.03.2015_End of Trial Declaration.pdf)

Trial information

Trial identification

Sponsor protocol code	2013AT001B

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Royal Brompton and Harefield NHS Foundation Trust, Royal Brompton Hospital
Sponsor organisation address	Research Office, Sydney Street, London , United Kingdom, SW3 6NP
Public contact	Ira Jakupovic, Royal Brompton and Harefield NHS Foundation Trust, +44 02073518109, i.jakupovic@rbht.nhs.uk
Scientific contact	Dr Andrew Menzies-Gow, Royal Brompton and Harefield NHS Foundation Trust, +44 02073518109, i.jakupovic@rbht.nhs.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 February 2015
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	26 February 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Is there a significant improvement lung function in severe asthmatic patients after receiving a course of IV Aminophylline and IV Hydrocortisone?

Protection of trial subjects:

The IMPs are drugs routinely given in practice. The dose or length of treatment will not be altered for the purposes of this study. There are risks associated with the use IV Aminophylline. These include toxicity, hypersensitivity, headache, confusion cardiac disturbances such as arrhythmias and palpitations, gastrointestinal disturbances, rash, and visual disturbances. There are also some risks associated with the use of IV Hydrocortisone. IV Hydrocortisone is usually given on a short-term basis, so it is unlikely that side-effects will occur; however, the patient will be monitored by the clinical team for possible risks, such as, hypersensitivity, gastrointestinal disturbance, alterations in blood chemistry and electrolytes, altered anti-inflammatory and immunosuppressive effects. The patient will be monitored by the clinical team in a ward area when receiving these drugs.
The IMPs are not being given to the patient for the purposes of research. Therefore the risks and side effects associated with these medicines will be monitored by the clinical team and acted on accordingly and in adherence with the study protocol.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 March 2014
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 4
Worldwide total number of subjects	4
EEA total number of subjects	4

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	4
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Patients have been recruited in line with the study protocol, from RBHT astham clinics.

Pre-assignment

Screening details:

4/4 patients screened, completed the study. Screening was undertaken in line with the study eligibility criteria.

Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Amynophillene/Hydrocortisone Arm

Arm description:

The SARAH study was designe to examine two well-known RBH prescribed therapies in combination for the treatment of asthma.

Arm type	Experimental
Investigational medicinal product name	Amynophylline hydrage 25mg/ml and Hydrocortisone sodium succinate for injection 100mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Patients are admitted for approximately 7 to 10 days for the treatment regimen. This is guided by the patient as an individual and by their symptoms. The dose of IV Hydrocortisone is guided by the dose of Prednisolone the patient is already taking, at 100mg twice a day (equivalent to 50mg Prednisolone) or 100mg three times a day (equivalent to 75mg Prednisolone).
The rate of Aminophylline is initially 0.5mg/kg/hour via continuous infusion and the dose is adjusted on a daily basis according to serum theophylline levels.

Number of subjects in period 1	Amynophillene/Hydrocortisone Arm
Started	4
Completed	4

Baseline characteristics

End points

End points reporting groups

Reporting group title	Amynophillene/Hydrocortisone Arm

Reporting group description:

The SARAH study was designe to examine two well-known RBH prescribed therapies in combination for the treatment of asthma.

Subject analysis set title	Overal trial
Subject analysis set type	Full analysis

Subject analysis set description:

insufficient number of patient recruited to conduct analysis

Primary: FEV1

End point title	FEV1[1]

End point description:

A mean of difference in FEV1 from baseline to a post treatment measure will be performed. A change in the FEV1 will be estimated using a paired t-test. There is no correction for multiple comparisons as the aim is not to assess efficacy. There is no predefined subgroup analysis.

End point type	Primary

End point timeframe:

Baseline to completion

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: It has not been possible to analyse data due to early termination, as outlined in the attached document, Annex 3.

End point values	Amynophillene/ Hydrocortisone Arm			
Subject group type	Reporting group			
Number of subjects analysed	4[2]			
Units: l/sec	0			

Notes:

[2] - insufficient number of pateints to conduct analysis

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]

Timeframe for reporting adverse events:

Duration of th study

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	17

Reporting groups

Reporting group title	Gastrointestinal

Reporting group description: -

Serious adverse events	Gastrointestinal		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 0.05 %

Non-serious adverse events	Gastrointestinal		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)		

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: This treatment is standard of care and we have noted that one patient experienced nausea as noted in the results section.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
23 December 2014	Changes made to the study prtocol, in relation to in relation to reporting of a serious breach, to ensure implementation of appropriate CAPAs.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
10 September 2014	Serious Breach GCP-14-068 reported by the Sponsor in relation to conduct of study procedure. It was noted that the breach had no impact on the safety of study patients or the integrity of the study data. It was felt that accumulation of issues required regulatory reporting.	-

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

This study was initially set up as an educational project. Unfortunatley, a study left employment prior to completion of the study. Due to early termination of the study, no meaningful data has been generated to allow analysis of results.

Notes: